Cinclus Pharma Joins Forces with Zentiva to Launch Linaprazan Glurate Across Europe

Cinclus Pharma has established a strategic partnership with Zentiva, a leading European pharmaceutical company, to commercialize and manufacture linaprazan glurate throughout Europe. This collaboration covers all member states of the European Economic Area (EEA), as well as the United Kingdom and Switzerland.

Linaprazan glurate, the flagship asset of Cinclus Pharma, is set to become more widely available to patients thanks to this partnership. Zentiva will be responsible for both manufacturing and distribution, utilizing its robust network and expertise within the pharmaceutical sector.

Key Highlights of the Partnership

• Covers all EEA countries, the UK, and Switzerland
• Zentiva to manage manufacturing and distribution
• Aims to accelerate patient access to linaprazan glurate
• Strengthens Cinclus Pharma’s presence in the European market

This agreement marks a significant milestone for Cinclus Pharma, showcasing its confidence in the potential of linaprazan glurate and expanding its footprint across Europe. Both companies anticipate that this alliance will enhance patient access to innovative treatments and foster stronger market positions for both partners.

For further developments, stay tuned to Questiqa Europe News for the latest updates.

About The Author